Results 11 to 20 of about 42,196 (291)
, 2016 Determining the optimal polyene antifungal dosing in obese patients is considered highly challenging. Limited data are available to describe the pharmacokinetics of polyene antifungals in these patients. However, polyene antifungals demonstrate widely variable pharmacokinetics in various clinical conditions.
Jamal, Janattul-Ain, Roberts, Jason A.
openaire +4 more sources
QJM: An International Journal of Medicine, 1995 Introduction Fungi have been recognized as pathogens for many years. However, the incidence of fungal infections in the pediatric population has increased substantially due to the increased use of broad-spectrum antibiotics, immunosuppressive agents, hyperalimentation products, and central venous catheters in addition to the acquired ...
J T, Cross, S L, Hickerson, T, Yamauchi
openaire +4 more sources
Antifungals of acromyrmex, allomerus, and tetraponera ant- and cultivarassociated bacteria [PDF]
, 2013 The central purpose of this thesis is to test the utility of ant-microbe associations for discovering antifungal compounds with novel molecular (sub-) structures.
Barke, Joerg
core +5 more sources
Frontiers in Cellular and Infection Microbiology, 2021 In many ways, fungal diseases are forgotten or neglected. Given the significantly lower frequency compared to similar bacterial etiologies across the spectrum of infectious syndromes, it makes sense that anti-bacterial agents have seen the bulk of development in recent decades.
Todd Patrick McCarty +2 more
openaire +3 more sources
Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer [PDF]
, 2021 Although breakthrough mucormycosis (BT-MCR) is known to develop on mold-active antifungals without Mucorales activity, it can also occur while on Mucorales-active antifungals.
Issam I. Raad +7 more
core +2 more sources
Journal of Fungi, 2021 Fungal infections represent an increasing public health crisis [...]
openaire +3 more sources
Approaches to detect alternative mechanisms of resistance to systemic antifungals [PDF]
, 2015 From the publisher\u27s website: Resistance to antifungals is a major concern in the management of fungal infections, especially while the incidence of pathogens with a poor susceptibility to current treatments is rising. New therapeutic strategies could
P. Vandeputte +2 more
core +3 more sources
, 2023 Clinically approved antifungals (gold), antifungals under clinical trials (green), and antifungals in preclinical studies (black).
Gerald F. Bills (128626) +2 more
core +1 more source
NOVEL SMALL MOLECULE ANTIFUNGALS FOR INVASIVE FUNGAL INFECTIONS [PDF]
, 2020 Human fungal pathogens cause a range of diseases from benign skin conditions (i.e., ringworm) to thrush, mucosal membrane infections, and life-threatening systemic infections including bloodstream infections (i.e., aspergillosis and candidiasis) and ...
Dennis, Emily
core +1 more source
Stress-Activated Protein Kinase Pathways as Potential Targets for the Development of New Antifungals. [PDF]
J Fungi (Basel)The World Health Organization WHO considers fungal infections as a significant global risk that necessitates the development of new therapies. The arsenal of antifungals is limited, and the eukaryotic organization of fungi makes it difficult to find ...
Alonso-Monge R +2 more
europepmc +2 more sources